ArticleJournal of biomedical nanotechnology2016
First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.
Article in Journal of biomedical nanotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Feasibility of MRI-Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer.Journal of magnetic resonance imaging : JMRI · 2025Article
- An Interventional Radiology Method for In Situ Assessments of Cancer Drug Response: Preclinical Development, Feasibility, and Safety.Radiology. Imaging cancer · 2025Article
- Review
- Gene Expression of GABABrain sciences · 2024Article
- Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.Science translational medicine · 2023Article
- Review
- Bendable long graded index lens microendoscopy.Optics express · 2022Article
- The Nervous System Contributes to the Tumorigenesis and Progression of Human Digestive Tract Cancer.Journal of immunology research · 2022Review
- The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients.IEEE transactions on bio-medical engineering · 2022Article
- Ligand-Gated Ion Channels as Targets for Treatment and Management of Cancers.Frontiers in physiology · 2022Review
- Intratarget Microdosing for Deep Phenotyping of Multiple Drug Effects in the Live Brain.Frontiers in bioengineering and biotechnology · 2022Article
- A Two-Photon Microimaging-Microdevice System for Four-Dimensional Imaging of Local Drug Delivery in Tissues.International journal of molecular sciences · 2021Article
- Therapeutically leveraging GABAExperimental biology and medicine (Maywood, N.J.) · 2021Review
- Long-GRIN-Lens Microendoscopy Enabled by Wavefront Shaping for a Biomedical Microdevice: An Analytical Investigation.Materials (Basel, Switzerland) · 2021Article
- Melanoma Cell Intrinsic GABAInternational journal of radiation oncology, biology, physics · 2021Article
- Article
- An interventional image-guided microdevice implantation and retrieval method for in-vivo drug response assessment.Medical physics · 2019Article
- Modulating native GABAJournal of neuro-oncology · 2019Article
- Genetically Encoded Fluorescent Proteins Enable High-Throughput Assignment of Cell Cohorts Directly from MALDI-MS Images.Analytical chemistry · 2019Article
- Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.Journal of hematology & oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 2 countries.
Funding
Abstract
Medulloblastoma is the most common childhood malignant brain tumor. The most lethal medulloblastoma subtype exhibits a high expression of the GABAA receptor α5 subunit gene and MYC amplification. New benzodiazepines have been synthesized to function as α5-GABAA receptor ligands. To compare their efficacy with that of standard-of-care treatments, we have employed a newly developed microscale implantable device that allows for high-throughput localized intratumor drug delivery and efficacy testing. Microdoses of each drug were delivered into small distinct regions of tumors, as confirmed by tissue mass spectrometry, and the local drug effect was determined by immunohistochemistry. We have identified a benzodiazepine derivative, KRM-II-08, as a new potent inhibitor in several α5-GABAA receptor expressing tumor models. This is the first instance of in vivo testing of several benzodiazepine derivatives and standard chemotherapeutic drugs within the same tumor. Obtaining high-throughput drug efficacy data within a native tumor microenvironment as detailed herein, prior to pharmacological optimization for bioavailability or safety and without systemic exposure or toxicity, may allow for rapid prioritization of drug candidates for further pharmacological optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.